Arthur Becker is the managing director of a renowned investment company called Madison Partners, LLC. The company is at its early stages of venturing into Bio Tech and real estate businesses. From 2012 to 2015, Arthur served as chief executive officer and chairman of Zinio, the largest digital newsstand in the world. Between 2002 and 2010, Becker was the chief executive officer of NaviSite Company that offered internet technology services, collocation, and hosting to various businesses in the United Kingdom and United States. For seven years, Becker was a senior adviser to Vera Wang Company. Since 2011, when NaviSite was sold to Time Warner, the executive has been a private investor in real estate and technology.
According to perezhilton.com, while working for NaviSite, Becker led the company through a secondary public offering. He also played a crucial role in ensuring that the company acquires eight corporations. He focused on expanding cloud services and the venture market of hosting solutions where he made huge revenues in 2010. Eventually, he transformed the company into a 150 million dollar business. During his tenure, Becker managed to maintain a zero percent voluntary turnover in his senior personnel. He served as the chief executive officer of NaviSite until 2010 when he resigned, but remained on company’s board until 2011
In 2006, Becker assumed operations and finance responsibilities for the Vera Wang Group. He succeeded in upgrading the management team and working closely with the founder of the company to support the growth of the firm. He was also able to revive the company from a 10 million dollar yearly loss to a 15 million dollar profit per year. Moreover, Becker reduced the expenses of Wang Vera Company by 35 percent and negotiated a 100 million dollar long-term license with a leading US retailer.
Similarly, while serving at Zinio, LLC in 2012, Becker was able to augment the company’s EBITDA, making it positive within the first two months of his appointment. Following his resignation from NaviSite, he started private investments in technology companies. His investments in biotech include C-4, which helps in deconstruction of targeted protein, Oncopep, a technology of cancer vaccine, and Frequency Therapeutics, which is a progenitor of cell motivation for restoring loss of hearing. Lately, he has been investing in the real estate industry, particularly housing developments in Miami and New York.